KDM6B and central nervous system cancer: showed that lysine-specific demethylase 6B (KDM6B) promoted the expression of key immunosuppressive factors in GAMs, including signal-regulatory protein α (Sirpa), suppressor of cytokine signaling 3 (Socs3), and v-Maf avian musculoaponeurotic fibrosarcoma oncogene homolog B (Mafb) (63), and that myeloid-specific ablation of KDM6B reprogrammed GAMs into anti-tumoral effectors, improving the efficacy of anti-PD1 treatment in glioma-bearing mice (34).